Medicinal Chemistry Journals: A Scopus and Web of Science Indexed List for 2026
This list covers 31 medicinal chemistry journals from our database, and only 10 of them are Q1. The other 21 sit in Q2, Q3 or Q4, and that gap shapes where your paper can realistically land. Below you get quartile, impact factor, first decision time and access type, so you can shortlist in minutes.
Quick answer: Start with Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry, ACS Medicinal Chemistry Letters, RSC Medicinal Chemistry or Bioorganic & Medicinal Chemistry. All five are Q1. Pick by article type first and quartile second. All 31 titles below are listed as Scopus and Web of Science indexed in our database as of November 2026.
What Are Medicinal Chemistry Journals, and What Do They Publish?
Medicinal chemistry journals publish work on how molecules become drugs: design, synthesis, structure-activity relationships, target engagement and early safety profiling. Some publish original studies, some only reviews, and some short letters. Knowing which type you are writing narrows a 31-title list to a handful of realistic targets.
Think of a drug program as a relay. Some journals take the early legs, such as synthesis, SAR and lead optimization. Others take the handoffs, such as ADMET profiling, screening and target validation. Review journals cover the whole track.
Drug design journals overlap heavily with this group. Chemical Biology & Drug Design and Letters in Drug Design & Discovery both appear below. Natural products work has a home too: Bioorganic Chemistry covers bioassay-guided isolation of phytochemicals, and our natural products journals category lists more.
Which Medicinal Chemistry Journals Are Indexed in Scopus and Web of Science?
In our database, all 31 titles below are indexed in Scopus and Web of Science as of November 2026. Twenty-six also list some form of PubMed coverage. The table sorts them by impact factor, with quartile, first decision time and access model beside each one.
| Journal | Publisher | IF | Quartile | First decision | Access |
|---|---|---|---|---|---|
| Medicinal Research Reviews | Wiley | 11.60 | Q1 | 2 weeks | Hybrid |
| Drug Discovery Today | Elsevier | 7.50 | Q1 | 2 weeks | Hybrid |
| Journal of Medicinal Chemistry | ACS | 6.80 | Q1 | 1 week | Hybrid |
| European Journal of Medicinal Chemistry | Elsevier | 5.90 | Q1 | 2 weeks | Hybrid |
| Expert Opinion on Therapeutic Patents | Taylor & Francis | 5.30 | Q1 | 3 weeks | Hybrid |
| Expert Opinion on Drug Discovery | Taylor & Francis | 5.00 | Q1 | 3 weeks | Hybrid |
| Bioorganic Chemistry | Elsevier | 4.70 | Q1 | 2 weeks | Hybrid |
| Journal of Enzyme Inhibition and Medicinal Chemistry | Taylor & Francis | 4.60 | Q2 | 2 weeks | Open access |
| ACS Medicinal Chemistry Letters | ACS | 4.00 | Q1 | 1 week | Hybrid |
| Molecular Diversity | Springer | 3.80 | Q2 | 3 weeks | Hybrid |
| Chemistry - A European Journal | Wiley-VCH | 3.70 | Q2 | 2 weeks | Hybrid |
| RSC Medicinal Chemistry | RSC | 3.60 | Q1 | 2 weeks | Hybrid |
| Archiv der Pharmazie | Wiley-VCH | 3.50 | Q2 | 3 weeks | Hybrid |
| Current Medicinal Chemistry | Bentham | 3.50 | Q2 | 3 weeks | Hybrid |
| ChemMedChem | Wiley-VCH | 3.40 | Q2 | 2 weeks | Hybrid |
| Drug Development Research | Wiley | 3.40 | Q3 | 5 weeks | Hybrid |
| Future Medicinal Chemistry | Future Science Group / Taylor & Francis | 3.40 | Q3 | 3 weeks | Hybrid |
| Chemical Biology & Drug Design | Wiley | 3.10 | Q2 | 3 weeks | Hybrid |
| Bioorganic & Medicinal Chemistry | Elsevier | 3.00 | Q1 | 2 weeks | Hybrid |
| Current Drug Targets | Bentham | 2.90 | Q2 | 3 weeks | Hybrid |
| Current Topics in Medicinal Chemistry | Bentham | 2.90 | Q2 | 3 weeks | Hybrid |
| Mini-Reviews in Medicinal Chemistry | Bentham | 2.70 | Q3 | 3 weeks | Hybrid |
| Bioorganic & Medicinal Chemistry Letters | Elsevier | 2.50 | Q2 | 2 weeks | Hybrid |
| CNS & Neurological Disorders - Drug Targets | Bentham | 2.50 | Q3 | 3 weeks | Hybrid |
| Anti-Cancer Agents in Medicinal Chemistry | Bentham | 2.30 | Q3 | 3 weeks | Hybrid |
| Journal of Heterocyclic Chemistry | Wiley | 2.30 | Q3 | 4 weeks | Hybrid |
| Combinatorial Chemistry & High Throughput Screening | Bentham | 2.10 | Q3 | 4 weeks | Hybrid |
| Medicinal Chemistry | Bentham | 2.00 | Q3 | 4 weeks | Hybrid |
| Synlett | Thieme | 1.70 | Q3 | 4 weeks | Hybrid |
| Letters in Drug Design & Discovery | Bentham | 1.40 | Q4 | 4 weeks | Hybrid |
| Pharmaceutical Chemistry Journal | Springer | 1.40 | Q3 | 3 weeks | Hybrid |
Source: Scientific Journal Finder database, November 2026. Impact factors may trail the latest JCR release, so confirm each value on the journal page. Quartiles can differ between Scopus and Web of Science.
Five titles do not list PubMed coverage: Molecular Diversity, Chemistry - A European Journal, Journal of Heterocyclic Chemistry, Synlett and Pharmaceutical Chemistry Journal. Check this if your funder requires PubMed-indexed output. Need more options? Our category page lists 134 medicinal chemistry and drug design journals.
Why Does the Quartile of a Medicinal Chemistry Journal Matter?
A quartile shows where a journal ranks among peers in one subject category. Q1 means the journal sits in the top 25% by impact factor, as Taylor & Francis defines it. Committees and funders often use it as a quick filter, and that filter shapes how your paper gets read.
Ten journals in this list are Q1. Four are review-led: Medicinal Research Reviews, Drug Discovery Today, Expert Opinion on Therapeutic Patents and Expert Opinion on Drug Discovery. Five take original research: Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry, Bioorganic Chemistry, RSC Medicinal Chemistry and Bioorganic & Medicinal Chemistry.
ACS Medicinal Chemistry Letters takes short communications. Elsevier holds four of the ten Q1 slots, and ACS holds two.
Here is the blunt part. Clarivate states that Journal Citation Reports indicators support journal evaluation, not the assessment of individual articles or researchers. A Q1 label tells you nothing about your paper. For a deeper look, read how quartile rankings work and compare Scopus versus Web of Science quartiles.
Is a Faster First Decision a Sign of a Weaker Journal?
No. In this list, speed and quartile move together. Eight of the 10 Q1 journals report a first decision within two weeks, and none of the 11 Q3 and Q4 titles reports a decision faster than three weeks. The two fastest, at one week, are both ACS titles.
| Quartile | Journals | 1 to 2 weeks | 3 weeks | 4 to 5 weeks |
|---|---|---|---|---|
| Q1 | 10 | 8 | 2 | 0 |
| Q2 | 10 | 4 | 6 | 0 |
| Q3 | 10 | 0 | 5 | 5 |
| Q4 | 1 | 0 | 0 | 1 |
That surprised me. Many authors assume the fast journals are the easy ones. My reading, not a measured result, is that large editorial offices triage quickly.
Here is the trade-off. A first decision can be a desk rejection, so a one-week figure means a fast answer, not a fast acceptance. Speed will not rescue a poor fit. If speed drives your choice, see our list of fast Scopus journals.
[AUTHOR: add real experience with a fast or slow decision]
What Mistakes Do Authors Make When Choosing a Drug Design Journal?
The most common mistake is choosing by impact factor alone. A scope mismatch can end a submission within days. Check scope, article type and the novelty bar before you format anything.
- Sending original data to a review journal. Medicinal Research Reviews publishes critical reviews, and Expert Opinion on Therapeutic Patents analyzes patent claims.
- Sending a docking-only study to a journal that wants experiments. Bioorganic & Medicinal Chemistry Letters accepts computational data closely linked to experimental results.
- Ignoring the novelty bar. RSC Medicinal Chemistry asks for a substantial advance, and ACS Medicinal Chemistry Letters stresses brevity and high novelty.
- Treating Q1 as one fixed label. The same journal can be Q1 in Scopus and Q2 in Web of Science.
- Skipping the rules. Read the author guidelines first. They save weeks.
How Do You Find the Right Medicinal Chemistry Journal for Your Manuscript?
Start from your manuscript, not from a ranking. Define your article type, match your abstract against journal scope, then filter by quartile, indexing and access model. Finally, read recent issues and the author guidelines. This sequence usually cuts a long list to three or four submission targets.
- Name your article type. Original research, review, letter or patent analysis.
- Write a short scope statement. Target class, method and main finding, in about 150 words.
- Run a journal search by abstract. Paste your abstract into the free journal finder. The journal finder tool scores it against aims and scope and returns the top 10 matches with quartile and first decision time.
- Cross-check against the table above. Drop anything with the wrong article type.
- Verify indexing and cost. Check Scopus Sources and Clarivate's Master Journal List. Then check the publisher's APC page, or see low-APC open access Scopus journals.
- Read two recent issues. If you cannot name three similar papers, skip the journal.
- Rank three targets and submit to one. Most journals prohibit simultaneous submission. For the wider method, see choosing the right journal.
What Changed for Journal Metrics in 2026?
Clarivate released Journal Citation Reports 2026 on June 17, 2026, based on 2025 citation data. The release covers 22,643 journals across 254 categories, and 521 journals received a Journal Impact Factor for the first time. Any impact factor in an older list may belong to a previous release.
Quartiles are recalculated each release, so a journal near the Q1/Q2 boundary can move. That is why I treat every list, including this one, as a starting point. Confirm the current value on the journal page before you submit.
My Take: Where I Would Submit First, and Where I Would Not
I would submit to the Q1 journal whose scope matches your paper most closely, even if another Q1 title has a higher impact factor. I think fit matters more than prestige. I would skip any journal where you cannot name three recent papers similar to yours.
Only about one in three journals here is Q1. Nine of the 31 titles come from Bentham, and none is Q1 in our database. Several suit focused reviews and letters, but I would confirm current quartile and indexing on Scopus Sources first.
The trade-off is time. Aiming at Q1 can cost a round of desk rejection, while a well-matched Q2 journal may accept sooner.
This advice does not apply if your funder or institution mandates a quartile, open access route or indexing database. Then policy decides. It also does not apply to clinical trial reports or pure analytical method papers, which belong in other categories.
Frequently Asked Questions About Medicinal Chemistry Journals
Which medicinal chemistry journal has the highest impact factor in this list?
Medicinal Research Reviews leads this list with a database impact factor of 11.60, followed by Drug Discovery Today at 7.50 and Journal of Medicinal Chemistry at 6.80. Medicinal Research Reviews publishes reviews, so original research belongs elsewhere. Confirm current values against the latest Journal Citation Reports release before you decide.
Which medicinal chemistry journals decide fastest?
Journal of Medicinal Chemistry and ACS Medicinal Chemistry Letters report the fastest first decision in this list at one week. Ten more report two weeks. First decision can include desk rejection, so it measures triage speed, not time to acceptance. Plan on longer for peer review.
Are there open access medicinal chemistry journals?
Journal of Enzyme Inhibition and Medicinal Chemistry is the only fully open access title in this list, and it sits in Q2 in our database. The other 30 are hybrid, so you can publish open access for a fee. Check each publisher's current APC page before you submit.
Which of these journals are indexed in PubMed?
Twenty-six of the 31 journals list PubMed, MEDLINE or PubMed Central coverage in our database. Molecular Diversity, Chemistry - A European Journal, Journal of Heterocyclic Chemistry, Synlett and Pharmaceutical Chemistry Journal do not. Check this if your funder requires PubMed-indexed publications.
Is Q1 necessary for a medicinal chemistry paper?
No. Q1 helps when a committee or funder sets a quartile rule, but fit and rigor matter more for acceptance. A well-matched Q2 journal often beats a mismatched Q1 submission that gets desk rejected. Check your institution's requirement first, then choose the journal whose recent papers resemble yours.
How do I find a journal for my manuscript by abstract?
Paste your abstract into a journal finder that scores it against journal aims and scope. Scientific Journal Finder returns the top 10 matches with quartile, citation metric and first decision time, and lets you filter by access type. Always confirm scope and indexing on the journal's own page afterward.
What You Should Do Next
Pick your article type, then shortlist three medicinal chemistry journals from the table whose recent papers resemble yours. Confirm quartile and indexing on each journal's own page before you format a single reference. Search your manuscript topic at scientificjournalfinder.com and find your best-matched journal in seconds.
Comments
No comments yet — be the first to share your thoughts.